article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Meath opened last month.

article thumbnail

APL Health Care (Aurobindo )-Walk-In Interviews for IPQA/ Microbiology On 4th Feb’ 2023

Pharma Pathway

APL Health Care (Aurobindo )-Walk-In Interviews for IPQA/ Microbiology On 4th Feb’ 2023 Job Description Company Profile: Aurobindo Pharma Ltd’ (APL). APL is a growing India multinational pharmaceutical manufacturing firm with turnover of over US$2.8

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Year in review: EPR’s top stories of 2023

European Pharmaceutical Review

At the beginning of this year, EPR reported on the potential blockbuster pharmaceutical drugs to watch in 2023. The year 2023 also brought much advancement in the Alzheimer’s space for the pharmaceutical industry. Since then, EPR has covered developments for several of the therapies highlighted in the report.

article thumbnail

Biosimilars Market Set for Biggest Year Yet in 2023

PM360

Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry. 2022 was a fascinating year for biosimilars, but may prove dull to 2023.

article thumbnail

ISPOR 2023: A Focus on Quality

Prognos Health

Todd Somsel , Commercial Lead, RWD Marketplace The acceptance and application of real-world evidence (RWE) by stakeholders across the healthcare industry continues its rapid pace of growth.

article thumbnail

ISPOR 2023: A Focus on Quality

Prognos Health

Todd Somsel , Commercial Lead, RWD Marketplace The acceptance and application of real-world evidence (RWE) by stakeholders across the healthcare industry continues its rapid pace of growth.

article thumbnail

Pharma unite to secure renewable energy in key manufacturing markets

European Pharmaceutical Review

For the first time, companies across the global healthcare sector, including AstraZeneca , GSK, Novo Nordisk and Roche, have united to discuss with energy providers in China and India, about scaling renewable power across their supply chains. This step is important as these countries are key markets for pharmaceuticals manufacturing.